Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 266 | 0.85 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9106
Sealed predictions
- SLC22A4 in dopamine neurons, braak-0.53 (p 0.145) → -0.39 (p 0.304)receipt 9113
Swarm cases
receipt 9113: SLC22A4 in dopamine neurons, braak
- power
- full sample -0.48 (p 0.042, n 18), 95% CI -0.78 to -0.02. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.47 (p 0.047, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.56 (p 0.016, n 18). not the mix.
- skeptic
- leave-one-out range -0.57 to -0.42, sign flips 0; without severely affected donors -0.48 (p 0.042, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC22A4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts